The introduction of generic sildenafil significantly reduced brand-name Viagra prescriptions. Studies show a substantial drop – approximately 50% – in brand-name prescriptions within a year of generic availability in various markets. This shift reflects patients’ preference for lower-cost alternatives.
Market Share Shift
Generic sildenafil captured a dominant market share, quickly becoming the preferred choice for many. This price-driven change demonstrates the significant influence of cost on medication choices, particularly for non-life-threatening conditions. The overall number of prescriptions for sildenafil (brand and generic combined) might have even increased due to improved accessibility.
Impact on Pharmaceutical Companies
Pfizer, the maker of Viagra, experienced a considerable decrease in revenue following generic competition. This financial impact highlights the challenges faced by pharmaceutical companies when patent protection expires. They often respond by developing new formulations or focusing on marketing existing drugs to specific patient groups.
